Janssen-Cilag S.p.A.

Quick facts

Marketed products

• Efavirenz (EFV) · Infectious Disease / Virology
  Efavirenz inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication.

Phase 3 pipeline

• Darunavir/Ritonavir (DRV/r) · Infectious Disease / Virology
  Darunavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Janssen-Cilag S.p.A. portfolio CI brief
• Janssen-Cilag S.p.A. pipeline updates RSS